Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Merck immune from antitrust claim that it misled FDA about mumps vaccine, court rules
Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...
BioSpace11h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
BioWorld3h
Merck’s clesrovimab tortoise to Beyfortus in RSV race?
Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
FiercePharma10d
Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...
Merck (MRK) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
Pharmabiz3d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Scoop2d
Merck Welcomes Funded Access To Cancer Treatment Erbitux® (Cetuximab)
“Merck has a strong heritage in oncology and our focus is bringing more medicines to patients with high unmet medical needs to improve and prolong lives. We believe those living with cancer ...